Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4590-4597

  Oudoux, Aurore ^a   Salaun, Pierre Yves ^b   Bournaud, Claire ^c   Campion, Loïc ^b   Ansquer, Catherine ^a   Rousseau, Caroline ^b   Bardet, Stéphane ^d   Borson Chazot, Françoise ^c   Vuillez, Jean Philippe ^e   Murat, Arnaud ^a   Mirallié, Eric ^a   Barbet, Jacques ^f   Goldenberg, David M ^g   Chatal, Jean François ^f   Kraeber Bodéré, Françoise ^a,b,f,h  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c Medical University   (France)

^d Cancer Institute   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^h INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; IODINE 131; PENTETATE IODINE I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CALCITONIN BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE DURATION; DRUG UPTAKE; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOSCINTIGRAPHY; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDIASTINUM METASTASIS; NECK METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; SENSITIVITY ANALYSIS; THYROID MEDULLARY CARCINOMA;

EID: 36849090954     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0938     Document Type: Article

References (41)

1. Marsh DJ, Learoyd DL, Robinson BG 1995 Medullary thyroid carcinoma: recent advances and management update. Thyroid 5:407-424
2. Lairmore TC, Wells Jr SA 1991 Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol 7:92-99
3. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM 1990 Long term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395-400
4. Saad MF, Fritsche HA, Samaan NA 1984 Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58:889-894
5. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, GTE Study Group 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084
6. Machens A, Gimm O, Ukkat J, Hinze R, Schneyer U, Dralle H 2000 Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88:1909-1915
7. Fleming J, Lee J, Bouvet M, Schultz P, Sherman S, Sellin R, Friend K, Burgess A, Cote G, Gagel R, Evans D 1999 Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 230:697-707
8. Raffaitin P, Hamy A, Mirallie E, Meurette G, Duplessis R, Lemeunier P, Murat A, Le Bodic M, Le Neel JC, Paineau J, Visset J 1999 Facteurs pronostiques de survie sans récidive clinique dans les cancers médullaires du corps thyroïde: à propos de 52 cas opérés. Ann Endocrinol (Paris) 60:435-442
9. Weber T, Schilling T, Franck-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R, Klar E 2001 Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 30:1044-1049
10. Schwerk WB, Grun R, Wahl R 1985 Ultrasound diagnosis of C-cell carcinoma of the thyroid. Cancer 55:624-630
11. Crow JP, Azar-Kia B, Prinz RA 1989 Recurrent occult thyroid carcinoma detected by MR imaging. AJR Am J Roentgenol 152:1255-1256
12. Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R 1992 Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2:113-117
13. Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R 1989 Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 21:31-34
14. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E 2005 Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23:70-78
15. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, Faivre-Chauvet A, Murat A, Charbonnel B, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodere F 2005 High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 90:779-788
16. Juweid ME, Cheson BD 2006 Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507
17. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E 2004 Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 48:150-163
18. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G 1998 Limited value of flurine-18 fluorodeoxyglucose PET for the imaging of neuroendocrine tumors. Eur J Nucl Med 25:79-83
19. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B 2000 Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med 44:68-76
20. Khan N, Oriuchi N, Higuchi T, Endo K 2005 Review of fluorine-18 -2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 12:254-260
21. Szakall Jr S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Agoston P, Tron L 2002 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
22. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A 2000 The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490-496
23. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT 2004 Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794
24. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F 2001 Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671-1676
25. Kraeber-Bodere F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardies M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF 1999 Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 5:3190-3198
26. Machens A, Gimm O, Ukkat J, Dralle H 1999 Repeat mediastinal lymph node dissection for palliation in advanced medullary thyroid carcinoma. Langenbecks Arch Surg 384:271-276
27. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G 2001 Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1798-1808
28. Moley JF, Dilley W, DeBenedetti M 1997 Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 225:734-743
29. Schlumberger M, Abdelmouene N, Delisle MJ, Couette JE 1995 Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 71:363-365
30. Wu LT, Averbuch SD, Ball DW, De Bustros A, Baylin SB, Mc Guire WP 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73:432-436
31. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J 2006 Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47:247-255
32. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J, French Endocrine Tumor Group 2006 Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy. J Clin Oncol 24:1705-1711
33. Simeone JF, Daniels GH, Hall DA, McCarthy K, Kopans DB, Butch RJ, Mueller PR, Stark DD, Ferrucci Jr JT, Wang CA 1987 Sonography in the follow-up of 100 patients with thyroid carcinoma. AJR Am J Roentgenol 148:45-49
34. Esik O, Szavcsur P, Szakall Jr S, Bajzik G, Repa I, Dabasi G, Fuzy M, Szentirmay Z, Perner F, Kasler M, Lengyel Z, Tron L 2001 Angiography effectively supports diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer 91:2084-2095
35. Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gônen M, Shaha AR, Tuttle RM, Shah JP, Larson SM 2007 Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48:501-507
36. Juweid M, Sharkey RM, Behr T, Swayne LC, Rubin AD, Herskovic T, Hanley D, Markowitz A, Dunn R, Siegel J, Kamal T, Goldenberg DM 1996 Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 14:1209-1217
37. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM 1996 Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 37:905-911
38. Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, Olivier P, Leccia F, Corcuff B, Huglo D, Proye C, Rouvier E, Meyer P, Chatal JF 1998 Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med 39:1172-1178
39. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790-1794
40. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Gorges R, Muller SP, Bockisch A, Debatin JF, Brandau W 2004 Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 14:2092-2098
41. 124I-labeled haptenpeptide. J Nucl Med 47:1678-1688